---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-265934"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-06-10T20:36:13+00:00"
generated_at: "2026-06-10T20:37:11.067354+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Intellia Therapeutics annual meeting elects three directors, ratifies auditor, passes say-on-pay

## Summary
- Elected Bhanji (57.1M for), Goff (46.1M), Goodman (43.0M) as Class I directors for three-year terms.
- Ratified Deloitte & Touche as auditor for FY2026 with 87.8M votes for.
- Advisory vote on executive compensation passed with 44.8M for, 13.8M against.

## SEC filing metadata
- accession: 0001193125-26-265934
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-06-10T20:36:13+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/0001193125-26-265934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/ntla-20260609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-265934
- JSON: https://secwatch.observer/filing/0001193125-26-265934.json
- Plain text: https://secwatch.observer/filing/0001193125-26-265934.txt

## Key facts
- Shareholder Votes
  Intellia Therapeutics, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The stockholders of the Company ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/0001193125-26-265934-index.htm
- Shareholder Votes
  Intellia Therapeutics, Inc. shareholders approved Election of Class I Directors at the 2026-06-09 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The stockholders of the Company elected each of Muna Bhanji, R.Ph., Brian Goff and Jesse Goodman, M.D., M.P.H., as a class I director, for a three-year term ending at the annual meeting of stockholders to be held in 2029 and until his or her successor has been duly elected and qualified or until his or her earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/0001193125-26-265934-index.htm
- Shareholder Votes
  Intellia Therapeutics, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-06-09 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-09
  source text: The stockholders of the Company approved, on a non-binding advisory basis, the compensation of our named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1652130/000119312526265934/0001193125-26-265934-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.